■ 学会名
The 67th Annual Meeting of the Japanese Society of Neurology (JSN 2026)

■ 発表日
2026/05/20

■ 筆頭演者
Saki Nakashima
Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

■ 共同演者
Satoshi Kodama²、Kenichiro Sato³,⁴、Yoshiki Niimi³,⁴、Shotaro Aso⁵、Hideo Yasunaga⁶、Yuichiro Shirota¹,⁷
、Masashi Hamada¹、Tatsushi Toda¹,⁸
1) Department of Neurology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
2) Department of Neurology, The University of Iowa Hospitals and Clinics, Iowa, United States
3) Unit for Early and Exploratory Development, The University of Tokyo Hospital, Tokyo, Japan
4) Dementia Inclusion and Therapeutics, The University of Tokyo Hospital, Tokyo, Japan
5) Department of Health Services Research, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
6) Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan
7) Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
8) National Center of Neurology and Psychiatry, Tokyo, Japan”

■ 発表形態
Oral presentation

■ 要旨
Enzyme-inducing antiseizure medications (EIASMs) may increase vascular risk, but evidence from Asian populations and from discrete cardiovascular outcomes has been limited. We conducted a retrospective cohort study using the Japanese DeSC claims database from April 2014 to May 2022. Adults with newly diagnosed epilepsy who initiated antiseizure medication were classified into EIASM and non-EIASM groups. After propensity score-based stabilized inverse probability weighting, 135,394 eligible patients were analyzed. Outcomes were acute myocardial infarction requiring PCI or CABG, cerebral infarction, intracerebral hemorrhage, and subarachnoid hemorrhage. EIASM use was associated with higher risks of acute myocardial infarction with revascularization, cerebral infarction, and intracerebral hemorrhage, while no significant association was observed for subarachnoid hemorrhage. These findings suggest that vascular risk may differ by event type and should be considered when selecting antiseizure medications, especially for patients with elevated cardiovascular risk.